PEOPLE - Exagen Diagnostics makes changes:
This article was originally published in Clinica
Albuquerque, New Mexico-based prognostic testing company Exagen Diagnostics has formed an advisory board to guide the development of prognostic products in the treatment of hepatitis C infection (HCV). The board consists of four physicians: Sanjeev Arora, who has been elected chairperson, Michael Fried, Robert Gish and Paul Pockros. The board will provide input on the firm's genomic marker programmes and clinical trials that impact treatment and management of hepatitis C.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.